Dual-targeted CAR T-cell immunotherapies for hematological malignancies : latest updates from the 2023 ASH annual meeting
© 2024. The Author(s)..
Over the past few years, dual-targeted chimeric antigen receptor (CAR) T-cell therapy has been employed in the management of hematological malignancies to mitigate treatment failure, particularly in cases of antigen escape. The most widely used approaches include CD19/CD20, CD20/CD22, and BCMA/CD19 CAR T-cells. Alternative immune cells, including natural killer T cells and invariant natural killer T cells, exhibit innate anti-tumor activity and reduced toxicity. This review summarizes several recent clinical trial reports and preclinical studies from the 2023 American Society of Hematology (ASH) annual meeting on dual-targeted CAR T-cell immunotherapy for hematological malignancies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Experimental hematology & oncology - 13(2024), 1 vom: 27. Feb., Seite 25 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Jingyi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chimeric antigen receptor |
|---|
| Anmerkungen: |
Date Revised 29.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s40164-024-00485-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369039122 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369039122 | ||
| 003 | DE-627 | ||
| 005 | 20240229235414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40164-024-00485-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1311.xml |
| 035 | |a (DE-627)NLM369039122 | ||
| 035 | |a (NLM)38413984 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Jingyi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dual-targeted CAR T-cell immunotherapies for hematological malignancies |b latest updates from the 2023 ASH annual meeting |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Over the past few years, dual-targeted chimeric antigen receptor (CAR) T-cell therapy has been employed in the management of hematological malignancies to mitigate treatment failure, particularly in cases of antigen escape. The most widely used approaches include CD19/CD20, CD20/CD22, and BCMA/CD19 CAR T-cells. Alternative immune cells, including natural killer T cells and invariant natural killer T cells, exhibit innate anti-tumor activity and reduced toxicity. This review summarizes several recent clinical trial reports and preclinical studies from the 2023 American Society of Hematology (ASH) annual meeting on dual-targeted CAR T-cell immunotherapy for hematological malignancies | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Chimeric antigen receptor | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Dual-targeted | |
| 650 | 4 | |a Hematological malignancy | |
| 700 | 1 | |a Guo, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yongping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Keshu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Experimental hematology & oncology |d 2012 |g 13(2024), 1 vom: 27. Feb., Seite 25 |w (DE-627)NLM223165115 |x 2162-3619 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:1 |g day:27 |g month:02 |g pages:25 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s40164-024-00485-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 1 |b 27 |c 02 |h 25 | ||